10-Q/A: Global Technologies Reports Q2 Loss Amid Strategic Shift

Global Technologies, Ltd. filed an amended quarterly report for Q2 2026, revealing a net loss for the quarter and a significant revenue decline, alongside a strategic pivot in its core operations.

Summary

• Global Technologies, Ltd. (GTLL) filed an amended Quarterly Report on Form 10-Q/A for the period ended December 31, 2025, incorporating revisions from an independent accounting firm review.
• The company reported a net loss of $144,760 for the three months ended December 31, 2025, compared to a net loss of $45,195 for the same period in 2024 (restated).
• Revenue for the three months ended December 31, 2025, decreased significantly to $345,968 from $917,077 in the prior year, primarily due to a strategic shift from a wholesale model to a direct-to-clinic sales strategy through its Primecare Supply subsidiary.
• For the six months ended December 31, 2025, net income was $21,439, a substantial decrease from $217,352 in the same period of 2024 (restated).
• Operating expenses increased to $273,320 for the three months ended December 31, 2025, from $170,802 in the prior year, and to $478,462 for the six months ended December 31, 2025, from $375,702 in the prior year.
• The company's cash and cash equivalents decreased to $41,408 as of December 31, 2025, from $68,108 as of June 30, 2025.
• Net cash used in operating activities for the six months ended December 31, 2025, was $226,600, a shift from $98,489 provided by operating activities in the prior year.
• The acquisition of GOe3, LLC, an EV charging station network, was terminated and cancelled on June 30, 2025, as GOe3 did not meet key operational and financial milestones.
• Primecare Supply, LLC, a B2B procurement company utilizing the Sinq Ops software platform, commenced operations in May 2025 and is now the company's primary revenue-generating subsidiary, focusing on connecting pharmaceutical manufacturers with medical clinics.
• GTLL Advisory Group, LLC, a strategic consulting and advisory platform, was formed in May 2025 and is expected to commence revenue-generating operations in fiscal year 2026.
• The company issued 200,000 shares of Series P Preferred Stock for cash proceeds of $200,000 on August 24, 2025, and an additional 30,000 shares for $30,000 on February 23, 2026.
• Disclosure controls and procedures were deemed not effective as of December 31, 2025, due to material weaknesses including a lack of resources, segregation of duties, and sufficient GAAP knowledge among personnel.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a negative sentiment due to significant revenue decline, increased operating losses, and a 'going concern' warning. While strategic shifts and capital raises offer future potential, current financial performance and internal control weaknesses are substantial concerns.

Positives

• The company successfully raised $200,000 through the issuance of 200,000 shares of Series P Preferred Stock on August 24, 2025, and an additional $30,000 on February 23, 2026.
• The strategic shift to a direct-to-clinic sales model for Primecare Supply, LLC, is expected to result in higher gross margins, stronger free cash flow, and long-term shareholder value, despite slower near-term revenue growth.
• Primecare Supply, LLC has diversified its customer base, with no single customer accounting for 10% or more of total revenues for the three months ended December 31, 2025, a significant improvement from 100% concentration in the prior year.
• The company expanded its supplier relationships for Primecare Supply, LLC, integrating multiple FDA-registered 503B outsourcing facilities, reducing reliance on a single supplier.
• The termination of the GOe3, LLC acquisition allowed Global Technologies to reallocate resources towards its core health technology, procurement, and strategic advisory services segments.
• The derivative liability decreased from $780,000 to $498,000, resulting in a gain of $282,000 for the six months ended December 31, 2025, contributing to the net income for the period.
• Total stockholders' deficiency improved from ($1,153,279) at June 30, 2025, to ($931,840) at December 31, 2025.

Negatives

• The company reported a net loss of $144,760 for the three months ended December 31, 2025, a significant increase from the restated net loss of $45,195 for the same period in 2024.
• Revenue for the three months ended December 31, 2025, decreased by 62.3% to $345,968 from $917,077 in the prior year, and for the six months, revenue decreased by 65.9% to $541,293 from $1,586,508.
• Net revenue for the six months ended December 31, 2025, decreased by 61.9% to $233,275 from $612,124 in the prior year.
• Operating expenses increased by 60% for the three months and 27.35% for the six months ended December 31, 2025, compared to the prior year.
• The company experienced a shift from income from operations of $236,422 for the six months ended December 31, 2024, to a loss from operations of $245,187 for the same period in 2025.
• Cash and cash equivalents decreased by $26,700 during the six months ended December 31, 2025, ending at $41,408.
• Net cash used in operating activities was $226,600 for the six months ended December 31, 2025, indicating a reliance on financing activities.
• The company has an accumulated deficit of $167,534,198 as of December 31, 2025, and a history of net losses, raising substantial doubt about its ability to continue as a going concern.
• Disclosure controls and procedures were deemed not effective, with material weaknesses identified, including a lack of resources, segregation of duties, and sufficient GAAP knowledge, posing risks to financial reporting accuracy.

Risks

• Substantial doubt exists about the company's ability to meet future financial obligations as they become due within one year, primarily due to a history of net losses and negative cash flows from operations.
• There is no assurance that sufficient additional funding will be generated from operations or available through external sources, which could force the company to curtail or cease operations.
• The company's disclosure controls and procedures were not effective as of December 31, 2025, due to material weaknesses, including insufficient personnel with GAAP knowledge and lack of segregation of duties, which could lead to failures in timely internal control and reviews.
• The company lacks an audit committee and independent outside directors on its Board of Directors, and documentation of its internal control processes is insufficient.
• The company's business model is subject to risks inherent in establishing new business plans through its operating subsidiaries, including financial risks associated with limited capital resources.
• The company relies on third-party suppliers, and purchases are concentrated among a limited number of these suppliers, posing a risk to supply chain stability.
• Convertible promissory notes totaling $300,000, plus significant accrued interest, are past their maturity dates (January 20, 2023, and February 22, 2023), indicating potential default or conversion risk.
• The company's ability to effectively execute its business plan, manage expansion and growth, protect its brands, and adapt to changes in technology and customer behavior are identified as important factors that could cause actual results to differ materially from forward-looking statements.

Future Outlook

Management expects GTLL Advisory Group, LLC to commence revenue-generating operations in fiscal year 2026. The strategic transition of Primecare Supply, LLC to a direct-to-clinic sales model is designed to generate more sustainable revenue, improved margins, stronger free cash flow, and long-term shareholder value as sales volumes scale and mature, despite anticipated slower near-term revenue growth. The company plans to secure additional funding through corporate partnerships, licensing agreements, convertible debentures, and equity securities to address its going concern uncertainty.

Management Comments

• Management believes Primecare Supply represents a core growth engine for Global Technologies, Ltd., offering scalable infrastructure, recurring transaction-based revenue, and a technology-enabled compliance advantage in the expanding health and wellness market.
• Management expects GTLL Advisory to commence revenue-generating operations in fiscal year 2026 as part of Globals expanding health-technology and advisory services portfolio.
• Management believes the decision to unwind the GOe3 acquisition allowed Global to reallocate resources toward its core business segments in health technology, procurement, and strategic advisory services.
• Management believes the transition to a direct-to-clinic sales strategy will result in slower near-term revenue growth but is designed to generate more sustainable revenue, improved margins, stronger free cash flow, and long-term shareholder value as sales volumes scale and mature.

Industry Context

StockSavvy.ai notes that Global Technologies' strategic pivot towards a direct-to-clinic B2B procurement model via Primecare Supply, leveraging its Sinq Ops software, positions it within the growing health and wellness technology sector. This move, following regulatory changes impacting GLP-1 products that affected its prior 10 Fold Services subsidiary, reflects an adaptation to evolving pharmaceutical supply chain dynamics. The focus on technology-enabled compliance and direct client relationships could provide a competitive edge in a fragmented market, contrasting with the broader industry trend of consolidation among larger pharmaceutical distributors. The planned launch of GTLL Advisory Group further diversifies its offerings into strategic consulting for medical spas and wellness clinics, aligning with the increasing demand for operational efficiency and technology integration in these specialized healthcare segments.

Comparison to Industry Standards

• The significant revenue decline for the three and six months ended December 31, 2025, contrasts sharply with growth trends seen in many established health technology and B2B procurement platforms, which often demonstrate consistent revenue expansion.
• The shift from a single customer accounting for 100% of revenue to multiple customers for Primecare Supply, LLC, aligns with best practices for revenue diversification, reducing concentration risk compared to industry peers heavily reliant on a few large contracts.
• The company's current cash position of $41,408 is significantly lower than typical working capital benchmarks for publicly traded companies, especially those undergoing strategic transitions and facing 'going concern' warnings, indicating a much weaker liquidity profile than most industry players.
• The identified material weaknesses in disclosure controls and internal control over financial reporting fall below acceptable industry standards for public companies, which typically maintain robust internal control frameworks to ensure financial reporting accuracy and compliance.

Corporate Governance

Legal Proceedings

• There is no pending litigation involving the company at this time.

Related Party Transactions

• Loans payable to officers/directors were reduced from $100 at June 30, 2025, to $0 at December 31, 2025.
• H. Wyatt Flippen, CEO and CFO, has an Executive Employment Agreement effective November 22, 2024, with a base salary of $8,500 per month and $125,000 worth of Series N Preferred Stock. Accrued compensation due to Mr. Flippen was $17,000 as of December 31, 2025, and June 30, 2025.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity raises to address going concern issues.
• Shareholders are impacted by the substantial doubt about the company's ability to continue as a going concern, which could lead to a loss of investment.
• Holders of Series P Preferred Stock are entitled to quarterly revenue share distributions equal to 5% of the net revenue of Primecare Supply, LLC and PulseAi, and 5% of the gross revenue of GTLL Advisory Group, LLC until they receive 200% of their original investment.
• Employees, particularly management, are impacted by the company's financial health and the need to secure additional funding to sustain operations.
• Customers of Primecare Supply, LLC benefit from the company's focus on streamlining the pharmaceutical supply chain and technology-enabled compliance, but may face uncertainty due to the company's financial condition.

Next Steps

• GTLL Advisory Group, LLC is expected to commence revenue-generating operations in fiscal year 2026.
• The company's Board of Directors is seeking to improve disclosure controls and procedures to remediate identified material weaknesses.
• Management plans to secure additional funding sources, including corporate partnerships, licensing agreements, convertible debentures, and equity securities, to address going concern uncertainty.

Key Dates

Recommendation

The filing presents a dire financial picture with a significant decline in revenue, increased operating losses, and a clear 'going concern' warning. The material weaknesses in internal controls and disclosure procedures are a severe red flag, indicating fundamental operational and governance issues. While the strategic shift and capital raises offer a potential path forward, the current financial instability and lack of robust controls make the stock a high-risk investment with substantial downside potential. A seasoned investor would likely view these factors as compelling reasons to exit or avoid the position.

Keywords

Global Technologies, GTLL, SEC Filing, 10-Q/A, Quarterly Report, Financial Results, Healthcare Technology, Wellness Industry, Pharmaceutical Supply Chain, Primecare Supply, GTLL Advisory Group, Sinq Ops, Corporate Governance, Risk Factors, Going Concern, Derivative Liability, Preferred Stock, Capital Raise, FDA Regulations, GLP-1, Internal Controls